港股医药板块早盘走强，港股创新药ETF（159567）一度涨逾2%

Group 1 - The Hong Kong pharmaceutical sector showed strength on November 24, with companies like 3SBio rising over 7% and Hengrui Medicine and Innovent Biologics increasing by more than 4% [1] - The Hong Kong Innovative Drug ETF (159567) rose approximately 2.2% by 9:51 AM, with a trading volume exceeding 300 million yuan [1] - As of last Friday, the product's shares increased by 1.105 billion shares this month, reaching a total of 9.922 billion shares, nearing the 10 billion mark [1] Group 2 - Institutions believe that the Chinese pharmaceutical industry has entered a critical phase of "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - Companies are actively exploring diversified overseas paths, with a focus on opportunities arising from innovation commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions by 2026 [1] - The Hong Kong Innovative Drug ETF (159567) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of listed companies in the innovative drug sector within the Stock Connect framework [1]